UK: CAT imposes competition remedy on Genzyme

On 29 September 2005 ,the Competition Appeal Tribunal (CAT) gave its judgment on the remedy to be imposed on Genzyme Limited, following the CAT's earlier decision on the merits of the case (which found that Genzyme had infringed UK competition law in pricing its Cerezyme drug and homecare services for administering Cerezyme).

This case concerns Genzyme's supply of drugs for the treatment of Gaucher's disease. The Office of Fair Trading (OFT) and CAT examined whether it was an abuse of Genzyme's dominance in that market to bundle the supply of Cerezyme with the provision of associated homecare services, and/or to charge independent third party homecare services providers a price for Cerezyme which allowed them no possible margin (a "margin squeeze")

The OFT found that Genzyme had abused its dominant position by bundling and by applying a margin squeeze (To view the article in full, please see below).

Full Article

Office of Fair Trading fines Genzyme £6.8m for exclusionary pricing behaviour

The Office of Fair Trading (OFT) has imposed a £6.8m fine on pharmaceutical producer Genzyme for exclusionary pricing behaviour in breach of Chapter II of the Competition Act 1998. This is the second fine imposed on a pharmaceutical company in relation to exclusionary practices in breach of the UK's prohibition of abuse of a dominant position. The first was a fine imposed on Napp for predatory and excessive pricing.

The fine concerned Genzyme's product Cerezyme which was until recently the only treatment for Gaucher disease, a rare inherited disorder. The OFT found that Genzyme held a dominant position in the market and abused this position by:

  • bundling the supply of Cerezyme with the provision of associated homecare services, thereby ensuring that only Genzyme could provide such services;
  • precluding third party competition by charging independent third party homecare service providers a price for Cerezyme which allowed them no possible margin.

The OFT found that such conduct excluded alternative home delivery providers and deprived the National Health Service (NHS) and patients of choice. It also raised entry barriers to alternative treatments of Gaucher disease.

The OFT issued directions which (inter alia) required Genzyme:

  • to offer to supply Cerezyme to the NHS at an unbundled, drug only, price;
  • to supply third parties at a price no higher than the unbundled price agreed with the UK Department of Health.

Genzyme appealed to the CAT, which in March 2004 disagreed with some of the OFT's findings but agreed that Genzyme had abused its dominance by applying a margin squeeze, reducing the fine to £3 million (To view the article in full, please see below).

Full Article

CAT reduces Genzyme's fine

On 11 March 2004, the Competition Appeal Tribunal (CAT) ruled on Genzyme's appeal against an earlier Office of Fair Trading (OFT) decision to fine the pharmaceutical company £6.8 million for breach of UK competition law. The CAT reduced Genzyme's fine to £3 million on the basis that the OFT had not sufficiently proved all parts of its case and on the basis that the abuse lasted for a shorter period than established by the OFT.

The OFT decided that Genzyme had infringed UK competition law by abusing its dominant position through bundling the cost of the drug and homecare services for administering the drug. It also found that Genzyme had abused its dominance by pricing the drug and homecare services at such a level that HH and other third parties could not make a profit on providing homecare services (a "margin squeeze").

In its 11 March judgment, the CAT found that the OFT had been correct to find that Genzyme had abused its dominance through the margin squeeze. However, the CAT continued that the OFT had not sufficiently proved that the bundling of the drug and the homecare services breached UK competition law, even though it facilitated the margin squeeze. It also decided that the abuse had lasted for a shorter period than the OFT had found.

For further details of the CAT's judgment of 11 March and its impact, please click here.

For the full text of the CAT's judgment, please click here.

The March 2004 judgment was confined to the merits of the case and the issue of remedies was adjourned for a separate hearing.

The CAT's judgment of September 2005 addresses this outstanding issue. The CAT noted that the adversarial position taken by Genzyme in relation to remedies meant that the remedies process took over eighteen months instead of the six weeks the CAT had originally envisaged. This was one of a number of reasons why the CAT decided that it was important to make a formal direction to Genzyme as to its future behaviour on the market to ensure that the infringement is brought to an end.

The CAT's direction ("the Direction") requires Genzyme to:

- no longer set a price for the supply of Cerezyme to providers of homecare services which results in a "margin squeeze" (this happens when the price charged is at a level where competitors as efficient as Genzyme are unable to make a profit on the homecare services);

- refrain from repeating that infringement or doing anything with equivalent effect;

- supply Cerezyme to any bona fide provider of homecare services at a drug-only price exclusive of any charge in respect of any element of homecare services and at a discount from the prevailing NHS list price for such drugs of at least 20 pence per unit; and

- ensure that sales of Cerezyme taking place by Genzyme to any Genzyme's former homecare business are on arm's length terms and on the same terms and conditions as trading with any other supplier of homecare services.

The OFT will monitor Genzyme's compliance with the Direction, and may modify or revoke any part of the Direction, although it may not revoke the Direction for the next three years without the CAT's consent.

This is the first time that the CAT has issued formal remedial directions under the Competition Act 1998.

For the text of the judgment (shorter version), please click on or copy and paste the link below:

This article was written for Law-Now, CMS Cameron McKenna's free online information service. To register for Law-Now, please go to

Law-Now information is for general purposes and guidance only. The information and opinions expressed in all Law-Now articles are not necessarily comprehensive and do not purport to give professional or legal advice. All Law-Now information relates to circumstances prevailing at the date of its original publication and may not have been updated to reflect subsequent developments.

The original publication date for this article was 04/10/2005.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions